Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases

NCT07008287 · clinicaltrials.gov ↗

RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Taletrectinib

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.